Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strate...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday.

If one looks at any place in the world where there is significant fundamental drug research happening from multinational firms, there is re...

Asserting that it's a really exciting moment to be in the world of medicine and R&D, Narasimhan said: "RNA therapeutics are opening up a wh...

Even as there is still question hanging over the efficacy of hydroxychloroquine (HCQ) as medication for Covid-19, Swiss drug maker Novartis...

Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-...

Novartis is one of the oldest pharma MNCs known for anti-cancer and anti-diabetic drugs. Despite the patent expiry for its popular anti-dia...

Vas Narasimhan from Novartis; Rajeev Suri from Nokia & Punit Renjen from Deloitte were part of the dinner that took place on the sidelines ...

Here’s everything that you need to know about the doctor-turned-CEO.

Jimenez is handing over the reins at a crucial juncture, with the drugmaker yet to make a decision on the future of its ailing Alcon eye-ca...

Novartis on Tuesday said it will buy GSK's oncology products business. Separately, Novartis said it will sell off its animal health divisio...

It says the price represents a 39 per cent premium over Genoptix's share value on Dec. 13, 2010, when rumors of a sale sparked a price surg...

Novartis on Thursday said it has concluded a $28.3 billion deal with Alcon Inc that will give the Swiss drug-maker a controlling stake in t...

Pharmaceuticals maker Novartis AG reported a 7 percent rise in first-quarter net income on Monday on the back of a declining dollar and sol...

Swedish government backs India in patent fight against pharma-major Novartis.

Swiss food giant Nestle is buying the Gerber baby food business off pharma major Novartis for $5.5 bn.

The final hearings on the Novartis petition challenging the clause of the Indian Patent Act Amendment (2005), which does not accord patents...